Boulevard Bio Launches with $65 Million from Deerfield and World-Class Founders to Advance Precision Immunology Pipeline
PR Newswire
NEW YORK, Aug. 12, 2026
World-class founding team includes Prof. Georg Schett, MD, a renowned expert in rheumatology, immunology, and B cell biology, alongside scientific co-founder and board member Frank Nestle, MD, Partner at Deerfield Management and CEO of Deerfield Discovery and Development (3DC)Early Phase 1 healthy volunteer data for BLVD101, lead candidate in IgAN, support best-in-class potential and 12-week (quarterly) dosingBLVD101 was invented by Deerfield Management within 3DC, the firm's drug discovery and development engineBoulevard is advancing a broad pipeline of multi-specific antibodies for B cell-driven autoimmune diseaseNEW YORK, Aug. 12, 2026 /PRNewswire/ -- Boulevard Bio today announced its emergence from stealth with $65 million from founding investor Deerfield Management and early Phase 1 healthy volunteer data for lead candidate BLVD101, a dual BAFF/APRIL-targeting bispecific antibody, supporting a 12-week (quarterly) dosing interval in IgA nephropathy (IgAN). Founded by pioneers in B cell biology and incubated by Deerfield Management within Deerfield Discovery and Development (3DC), the firm's internal therapeutics research and development engine, Boulevard's approach is grounded in a deep understanding of B cell disease biology, the identification of key mechanisms and targets that drive pathology, and the ability to engineer multi-specific antibodies to address those drivers. The company aims to optimize each of the three candidates in its pipeline to improve the quality of life a chronic illness often erodes.
